메뉴 건너뛰기




Volumn 29, Issue 9, 2012, Pages 723-735

Bevacizumab in the treatment of ovarian cancer

Author keywords

Antiangiogenic therapy; Bevacizumab; Carcinoma; Ovarian cancer

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ERLOTINIB; GEMCITABINE; PACLITAXEL; PLACEBO; TOPOTECAN; VASCULOTROPIN;

EID: 84866479731     PISSN: 0741238X     EISSN: 18658652     Source Type: Journal    
DOI: 10.1007/s12325-012-0041-9     Document Type: Review
Times cited : (30)

References (50)
  • 1
    • 84866493384 scopus 로고
    • The reluctant surgeon
    • Garden City, New York: Doubleday & Company, Inc
    • Kober J. The reluctant surgeon. A biography of John Hunter. Garden City, New York: Doubleday & Company, Inc.; 1960.
    • (1960) A Biography Of John Hunter
    • Kober, J.1
  • 3
    • 84944482999 scopus 로고
    • The transparent chamber of the rabbits ear, giving a complete description of improved technic of construction and introduction, and general account of growth and behavior of living cells and tissues as seen with the microscope
    • Sandison J. The transparent chamber of the rabbits ear, giving a complete description of improved technic of construction and introduction, and general account of growth and behavior of living cells and tissues as seen with the microscope. Am J Anat. 1928;41:447-72.
    • (1928) Am J Anat , vol.41 , pp. 447-72
    • Sandison, J.1
  • 4
    • 0000912662 scopus 로고
    • Vascularization of the Brown-Pearce rabbit epitheioma transplant as seen in the transparent ear chamber
    • Ide A, Baker N, Warren S, et al. Vascularization of the Brown-Pearce rabbit epitheioma transplant as seen in the transparent ear chamber. Am J Roentgenol. 1939;42:891-9.
    • (1939) Am J Roentgenol , vol.42 , pp. 891-9
    • Ide, A.1    Baker, N.2    Warren, S.3
  • 5
    • 0015008620 scopus 로고
    • Isolation of a tumor factor responsible for angiogenesis
    • Folkman J, Merler E, Abernathy C, Williams G. Isolation of a tumor factor responsible for angiogenesis. J Exp Med. 1971;133:275-88.
    • (1971) J Exp Med , vol.133 , pp. 275-88
    • Folkman, J.1    Merler, E.2    Abernathy, C.3    Williams, G.4
  • 6
    • 0024384470 scopus 로고
    • Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells
    • DOI 10.1016/0006-291X(89)92678-8
    • Ferrara N, Henzel WJ. Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. Biochem Biophys Res Commun. 1989;161:851-8. (Pubitemid 19162712)
    • (1989) Biochemical and Biophysical Research Communications , vol.161 , Issue.2 , pp. 851-858
    • Ferrara, N.1    Henzel, W.J.2
  • 7
  • 8
    • 19744368302 scopus 로고    scopus 로고
    • Cancer of the ovary
    • Cannistra SA. Cancer of the ovary. N Engl J Med. 2004;351:2519-29.
    • (2004) N Engl J Med , vol.351 , pp. 2519-29
    • Cannistra, S.A.1
  • 9
    • 63449129599 scopus 로고    scopus 로고
    • Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: A combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: By the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGOOVAR) and the Groupe d'Investigateurs Nationaux Pour les Etudes des Cancers de l'Ovaire (GINECO)
    • du Bois A, Reuss A, Pujade-Lauraine E, Harter P, Ray-Coquard I, Pfisterer J. Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: A combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGOOVAR) and the Groupe d'Investigateurs Nationaux Pour les Etudes des Cancers de l'Ovaire (GINECO). Cancer. 2009;115:1234-44.
    • (2009) Cancer , vol.115 , pp. 1234-44
    • Du Bois, A.1    Reuss, A.2    Pujade-Lauraine, E.3    Harter, P.4    Ray-Coquard, I.5    Pfisterer, J.6
  • 10
    • 77956285631 scopus 로고    scopus 로고
    • Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer
    • Vergote I, Trope CG, Amant F, et al. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med. 2010;363:943-53.
    • (2010) N Engl J Med , vol.363 , pp. 943-53
    • Vergote, I.1    Trope, C.G.2    Amant, F.3
  • 11
    • 0041329867 scopus 로고    scopus 로고
    • A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer
    • du Bois A, Luck HJ, Meier W, et al. A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. J Natl Cancer Inst. 2003;95:1320-9.
    • (2003) J Natl Cancer Inst , vol.95 , pp. 1320-9
    • Du Bois, A.1    Luck, H.J.2    Meier, W.3
  • 13
    • 77950654584 scopus 로고    scopus 로고
    • TIMP-1 and VEGF-165 serum concentration during first- line therapy of ovarian cancer patients
    • Mahner S, Woelber L, Eulenburg C, et al. TIMP-1 and VEGF-165 serum concentration during first- line therapy of ovarian cancer patients. BMC Cancer. 2010;10:139.
    • (2010) BMC Cancer , vol.10 , pp. 139
    • Mahner, S.1    Woelber, L.2    Eulenburg, C.3
  • 15
    • 0033061333 scopus 로고    scopus 로고
    • Serum preoperative vascular endothelial growth factor (VEGF) in epithelial ovarian cancer: Relationship with prognostic variables and clinical outcome
    • Gadducci A, Ferdeghini M, Fanucchi A, et al. Serum preoperative vascular endothelial growth factor (VEGF) in epithelial ovarian cancer: Relationship with prognostic variables and clinical outcome. Anticancer Res. 1999;19:1401-5. (Pubitemid 29257466)
    • (1999) Anticancer Research , vol.19 , Issue.2 B , pp. 1401-1405
    • Gadducci, A.1    Ferdeghini, M.2    Fanucchi, A.3    Annicchiarico, C.4    Ciampi, B.5    Prontera, C.6    Genazzani, A.R.7
  • 16
    • 59449084872 scopus 로고    scopus 로고
    • Maintenance treatment with bevacizumab prolongs survival in an in vivo ovarian cancer model
    • Mabuchi S, Terai Y, Morishige K, et al. Maintenance treatment with bevacizumab prolongs survival in an in vivo ovarian cancer model. Clin Cancer Res. 2008;14:7781-9.
    • (2008) Clin Cancer Res , vol.14 , pp. 7781-9
    • Mabuchi, S.1    Terai, Y.2    Morishige, K.3
  • 17
    • 79957457473 scopus 로고    scopus 로고
    • Die Qualität der Therapie des Ovarialkarzinoms in Deutschland
    • du Bois A, Rochon J, Lamparter C, et al. Die Qualität der Therapie des Ovarialkarzinoms in Deutschland. Frauenarzt. 2009;50:742-51.
    • (2009) Frauenarzt , vol.50 , pp. 742-51
    • Du Bois, A.1    Rochon, J.2    Lamparter, C.3
  • 18
    • 73949092398 scopus 로고    scopus 로고
    • Phase II study of carboplatin, paclitaxel, and bevacizumab with maintenance bevacizumab as first-line chemotherapy for advanced mullerian tumors
    • Penson RT, Dizon DS, Cannistra SA, et al. Phase II study of carboplatin, paclitaxel, and bevacizumab with maintenance bevacizumab as first-line chemotherapy for advanced mullerian tumors. J Clin Oncol. 2010;28:154-9.
    • (2010) J Clin Oncol , vol.28 , pp. 154-9
    • Penson, R.T.1    Dizon, D.S.2    Cannistra, S.A.3
  • 19
    • 79960679604 scopus 로고    scopus 로고
    • A pilot study evaluating a novel regimen comprised of carboplatin, paclitaxel, and bevacizumab for advanced-stage ovarian carcinoma
    • Brown JV III, Micha JP, Rettenmaier MA, Abaid LN, Lopez KL, Goldstein BH. A pilot study evaluating a novel regimen comprised of carboplatin, paclitaxel, and bevacizumab for advanced-stage ovarian carcinoma. Int J Gynecol Cancer. 2010;20:1132-36.
    • (2010) Int J Gynecol Cancer , vol.20 , pp. 1132-36
    • Brown III, J.V.1    Micha, J.P.2    Rettenmaier, M.A.3    Abaid, L.N.4    Lopez, K.L.5    Goldstein, B.H.6
  • 21
    • 83355169742 scopus 로고    scopus 로고
    • Phase II study of intraperitoneal paclitaxel plus cisplatin and intravenous paclitaxel plus bevacizumab as adjuvant treatment of optimal stage II/III epithelial ovarian cancer
    • Konner JA, Grabon DM, Gerst SR, et al. Phase II study of intraperitoneal paclitaxel plus cisplatin and intravenous paclitaxel plus bevacizumab as adjuvant treatment of optimal stage II/III epithelial ovarian cancer. J Clin Oncol. 2011;29:4662-8.
    • (2011) J Clin Oncol , vol.29 , pp. 4662-8
    • Konner, J.A.1    Grabon, D.M.2    Gerst, S.R.3
  • 22
    • 84855425106 scopus 로고    scopus 로고
    • Incorporation of bevacizumab in the primary treatment of ovarian cancer
    • Burger RA, Brady MF, Bookman MA, et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med. 2011;365:2473-83.
    • (2011) N Engl J Med , vol.365 , pp. 2473-83
    • Burger, R.A.1    Brady, M.F.2    Bookman, M.A.3
  • 23
    • 84855466019 scopus 로고    scopus 로고
    • A phase 3 trial of bevacizumab in ovarian cancer
    • Perren TJ, Swart AM, Pfisterer J, et al. A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med. 2011;365:2484-96.
    • (2011) N Engl J Med , vol.365 , pp. 2484-96
    • Perren, T.J.1    Swart, A.M.2    Pfisterer, J.3
  • 24
    • 84874190315 scopus 로고    scopus 로고
    • Evaluation of Optimal Initial Treatment Duration of Bevacizumab in Combination With Standard Chemotherapy in Patients With Ovarian Cancer (BOOST)
    • AGO Study Group Available at: Accessed June 1 2012
    • AGO Study Group. Evaluation of Optimal Initial Treatment Duration of Bevacizumab in Combination With Standard Chemotherapy in Patients With Ovarian Cancer (BOOST). ClinicalTrials no. NCT01462890. Available at: http://clinicaltrials.gov/ct2/show/NCT01462890. Accessed June 1 2012.
    • Clinical Trials no NCT01462890
  • 28
    • 80051913984 scopus 로고    scopus 로고
    • 2010 Gynecologic Cancer InterGroup (GCIG) Consensus Statement on Clinical Trials in Ovarian Cancer: Report From the Fourth Ovarian Cancer Consensus Conference
    • Stuart GC, Kitchener H, Bacon M, et al. 2010 Gynecologic Cancer InterGroup (GCIG) Consensus Statement on Clinical Trials in Ovarian Cancer: Report From the Fourth Ovarian Cancer Consensus Conference. Int J Gynecol Cancer. 2011;21:750-5.
    • (2011) Int J Gynecol Cancer , vol.21 , pp. 750-5
    • Stuart, G.C.1    Kitchener, H.2    Bacon, M.3
  • 29
    • 67549084366 scopus 로고    scopus 로고
    • Topotecan versus treosulfan, an alkylating agent, in patients with epithelial ovarian cancer and relapse within 12 months following 1st-line platinum/paclitaxel chemotherapy. A prospectively randomized phase III trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group (AGO-OVAR)
    • Meier W, du Bois A, Reuss A, et al. Topotecan versus treosulfan, an alkylating agent, in patients with epithelial ovarian cancer and relapse within 12 months following 1st-line platinum/paclitaxel chemotherapy. A prospectively randomized phase III trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group (AGO-OVAR). Gynecol Oncol. 2009;114:199-205.
    • (2009) Gynecol Oncol , vol.114 , pp. 199-205
    • Meier, W.1    Du Bois, A.2    Reuss, A.3
  • 33
    • 0037862963 scopus 로고    scopus 로고
    • Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: The ICON4/AGO-OVAR-2.2 trial
    • Parmar MK, Ledermann JA, Colombo N, et al. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: The ICON4/AGO-OVAR-2.2 trial. Lancet. 2003;361:2099-106.
    • (2003) Lancet , vol.361 , pp. 2099-106
    • Parmar, M.K.1    Ledermann, J.A.2    Colombo, N.3
  • 35
    • 77954726606 scopus 로고    scopus 로고
    • Pegylated liposomal doxorubicin and carboplatin compared with paclitaxel and carboplatin for patients with platinum-sensitive ovarian cancer in late relapse
    • Pujade-Lauraine E, Wagner U, Aavall-Lundqvist E, et al. Pegylated liposomal doxorubicin and carboplatin compared with paclitaxel and carboplatin for patients with platinum-sensitive ovarian cancer in late relapse. J Clin Oncol. 2010;28:3323-9.
    • (2010) J Clin Oncol , vol.28 , pp. 3323-9
    • Pujade-Lauraine, E.1    Wagner, U.2    Aavall-Lundqvist, E.3
  • 38
    • 37849035249 scopus 로고    scopus 로고
    • Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: A trial of the California, Chicago, and Princess Margaret Hospital phase II consortia
    • Garcia AA, Hirte H, Fleming G, et al. Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: A trial of the California, Chicago, and Princess Margaret Hospital phase II consortia. J Clin Oncol. 2008;26:76-82.
    • (2008) J Clin Oncol , vol.26 , pp. 76-82
    • Garcia, A.A.1    Hirte, H.2    Fleming, G.3
  • 39
    • 36849019301 scopus 로고    scopus 로고
    • Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: A Gynecologic Oncology Group study
    • DOI 10.1200/JCO.2007.11.5345
    • Burger RA, Sill MW, Monk BJ, Greer BE, Sorosky JI. Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: A Gynecologic Oncology Group Study. J Clin Oncol. 2007;25:5165-71. (Pubitemid 350237599)
    • (2007) Journal of Clinical Oncology , vol.25 , Issue.33 , pp. 5165-5171
    • Burger, R.A.1    Sill, M.W.2    Monk, B.J.3    Greer, B.E.4    Sorosky, J.I.5
  • 40
    • 35348904080 scopus 로고    scopus 로고
    • Bevacizumab plus cyclophosphamide in heavily pretreated patients with recurrent ovarian cancer
    • DOI 10.1016/j.ygyno.2007.07.017, PII S0090825807004635
    • Chura JC, Van Iseghem K, Downs LS Jr, Carson LF, Judson PL. Bevacizumab plus cyclophosphamide in heavily pretreated patients with recurrent ovarian cancer. Gynecol Oncol. 2007;107:326-30. (Pubitemid 47575735)
    • (2007) Gynecologic Oncology , vol.107 , Issue.2 , pp. 326-330
    • Chura, J.C.1    Van Iseghem, K.2    Downs Jr., L.S.3    Carson, L.F.4    Judson, P.L.5
  • 41
    • 45549099056 scopus 로고    scopus 로고
    • Efficacy and safety of bevacizumab plus erlotinib for patients with recurrent ovarian, primary peritoneal, and fallopian tube cancer: A trial of the Chicago, PMH, and California Phase II Consortia
    • Nimeiri HS, Oza AM, Morgan RJ, et al. Efficacy and safety of bevacizumab plus erlotinib for patients with recurrent ovarian, primary peritoneal, and fallopian tube cancer: A trial of the Chicago, PMH, and California Phase II Consortia. Gynecol Oncol. 2008;110:49-55.
    • (2008) Gynecol Oncol , vol.110 , pp. 49-55
    • Nimeiri, H.S.1    Oza, A.M.2    Morgan, R.J.3
  • 42
    • 67651055473 scopus 로고    scopus 로고
    • Prognostic importance of vascular endothelial growth factor-A expression and vascular endothelial growth factor polymorphisms in epithelial ovarian cancer
    • Smerdel MP, Waldstrom M, Brandslund I, Steffensen KD, Andersen RF, Jakobsen A. Prognostic importance of vascular endothelial growth factor-A expression and vascular endothelial growth factor polymorphisms in epithelial ovarian cancer. Int J Gynecol Cancer. 2009;19:578-84.
    • (2009) Int J Gynecol Cancer , vol.19 , pp. 578-84
    • Smerdel, M.P.1    Waldstrom, M.2    Brandslund, I.3    Steffensen, K.D.4    Andersen, R.F.5    Jakobsen, A.6
  • 43
    • 79960473821 scopus 로고    scopus 로고
    • Effects of bevacizumab and pegylated liposomal doxorubicin for the patients with recurrent or refractory ovarian cancers
    • Kudoh K, Takano M, Kouta H, et al. Effects of bevacizumab and pegylated liposomal doxorubicin for the patients with recurrent or refractory ovarian cancers. Gynecol Oncol. 2011;122:233-7.
    • (2011) Gynecol Oncol , vol.122 , pp. 233-7
    • Kudoh, K.1    Takano, M.2    Kouta, H.3
  • 44
    • 80053935580 scopus 로고    scopus 로고
    • Pegylated liposomal doxorubicin (PLD) with bevacizumab (B) in second-line treatment of ovarian cancer (OC): Pharmacokinetics (PK), safety, and preliminary outcome results
    • Abstract 5548
    • Muggia FM, Boyd L, Liebes L, et al. Pegylated liposomal doxorubicin (PLD) with bevacizumab (B) in second-line treatment of ovarian cancer (OC): Pharmacokinetics (PK), safety, and preliminary outcome results. J Clin Oncol 2009;27 (Suppl.):15s (Abstract 5548).
    • (2009) J Clin Oncol , vol.27 , Issue.SUPPL.15
    • Muggia, F.M.1    Boyd, L.2    Liebes, L.3
  • 45
    • 80051549914 scopus 로고    scopus 로고
    • Combined weekly topotecan and biweekly bevacizumab in women with platinumresistant ovarian, peritoneal, or fallopian tube cancer: Results of a phase 2 study
    • McGonigle KF, Muntz HG, Vuky J, et al. Combined weekly topotecan and biweekly bevacizumab in women with platinumresistant ovarian, peritoneal, or fallopian tube cancer: Results of a phase 2 study. Cancer. 2011;117:3731-40.
    • (2011) Cancer , vol.117 , pp. 3731-40
    • McGonigle, K.F.1    Muntz, H.G.2    Vuky, J.3
  • 46
    • 84864396971 scopus 로고    scopus 로고
    • A phase II clinical trial of pegylated liposomal doxorubicin and carboplatin plus bevacizumab in patients with platinumsensitive recurrent ovarian, fallopian tube, or primary peritoneal cancer
    • Del Carmen MG, Micha J, Small L, Street DG, Londhe A, McGowan T. A phase II clinical trial of pegylated liposomal doxorubicin and carboplatin plus bevacizumab in patients with platinumsensitive recurrent ovarian, fallopian tube, or primary peritoneal cancer. Gynecol Oncol. 2012;126:369-74.
    • (2012) Gynecol Oncol , vol.126 , pp. 369-74
    • Del Carmen, M.G.1    Micha, J.2    Small, L.3    Street, D.G.4    Londhe, A.5    McGowan, T.6
  • 47
    • 80053229517 scopus 로고    scopus 로고
    • OCEANS: A randomized, double-blinded, placebocontrolled phase III trial of chemotherapy with or without bevacizumab (BEV) in patients with platinum-sensitive recurrent epithelial ovarian (EOC), primary peritoneal (PPC), or fallopian tube cancer (FTC)
    • Abstract LBA5007
    • Aghajanian C, Finkler N, Rutherford T, et al. OCEANS: A randomized, double-blinded, placebocontrolled phase III trial of chemotherapy with or without bevacizumab (BEV) in patients with platinum-sensitive recurrent epithelial ovarian (EOC), primary peritoneal (PPC), or fallopian tube cancer (FTC). J Clin Oncol. 2011;29 (Suppl.). Abstract LBA5007.
    • (2011) J Clin Oncol , vol.29 , Issue.SUPPL.
    • Aghajanian, C.1    Finkler, N.2    Rutherford, T.3
  • 48
    • 84866493383 scopus 로고    scopus 로고
    • AURELIA: A randomized phase III trial evaluating bevacizumab (BEV) plus chemotherapy (CT) for platinum (PT)-resistant recurrent ovarian cancer (OC)
    • Abstract LBA5002
    • Pujade-Lauraine E, Hilpert F, Weber B, Reuss A, Poveda A, Kristensen G. AURELIA: A randomized phase III trial evaluating bevacizumab (BEV) plus chemotherapy (CT) for platinum (PT)-resistant recurrent ovarian cancer (OC). J Clin Oncol 2012;30(Suppl.). Abstract LBA5002.
    • (2012) J Clin Oncol , vol.30 , Issue.SUPPL.
    • Pujade-Lauraine, E.1    Hilpert, F.2    Weber, B.3    Reuss, A.4    Poveda, A.5    Kristensen, G.6
  • 49
    • 79953863317 scopus 로고    scopus 로고
    • Big costs for little gain in ovarian cancer
    • Hensley ML. Big costs for little gain in ovarian cancer. J Clin Oncol. 2011;29:1230-2.
    • (2011) J Clin Oncol. , vol.29 , pp. 1230-2
    • Hensley, M.L.1
  • 50
    • 79953893326 scopus 로고    scopus 로고
    • At what cost does a potential survival advantage of bevacizumab make sense for the primary treatment of ovarian cancer? A cost-effectiveness analysis
    • Cohn DE, Kim KH, Resnick KE, O'Malley DM, Straughn JM Jr. At what cost does a potential survival advantage of bevacizumab make sense for the primary treatment of ovarian cancer? A cost-effectiveness analysis. J Clin Oncol. 2011;29:1247-51.
    • (2011) J Clin Oncol. , vol.29 , pp. 1247-51
    • Cohn, D.E.1    Kim, K.H.2    Resnick, K.E.3    O'Malley, D.M.4    Straughn Jr., J.M.5


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.